Frontlight ResearchEarly access
CompletedNo phase
Long-term Follow-up of Phase 1 Clinical Trial of CS10BR05(CS10BR05-MSA101)
Key facts
- Who runs it
- Corestemchemon, Inc.
- Where
- South Korea1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 8 people enrolled
- Started
- 28 Aug 2018
- Ended
- 25 Sept 2024
- Type of study
- Observational
- Record updated
- 7 January 2025
Who can take part
- Sex
- Women and men
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Subjects who participated in the phase 1 clinical trial(Protocol No.: CS10BR05- MSA101) at 3 months after administering investigational product
- Subjects who give a written, signed and dated informed consent spontaneously
Who cannot take part
- Subjects who decided as inappropriate cases to participate in the observational study by investigator
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The study purpose is conducting follow-up surveillance for the incidence of adverse events and efficacy of subjects participated in phase 1 trial to evaluate the safety and tolerability of autologous bone marrow-derived mesenchymal stem cells (CS10BR05) in subjects with Multiple System Atrophy until 60 months from administering investigational product (IP).
The group in the trial
- Non-Interventional Study group
Subjects participating in this observational study originally participated in CS10BR05 Inj. phase 1 study.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Observational Study of Long-term Safety and Efficacy of Subjects Who Participated in CS10BR05 Inj. Phase 1 Study
- Record updated
- 7 January 2025